JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266996

Human TRIM22 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TRIM22 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 8 bp deletion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human TRIM22 knockout A549 cell line (AB266996)
  • Sanger seq

Unknown

Sanger Sequencing - Human TRIM22 knockout A549 cell line (AB266996)

Allele-2 : 1 bp insertion in exon 3.

Sanger Sequencing - Human TRIM22 knockout A549 cell line (AB266996)
  • Sanger seq

Unknown

Sanger Sequencing - Human TRIM22 knockout A549 cell line (AB266996)

Allele-1 : 8 bp deletion in exon3

Sanger Sequencing - Human TRIM22 knockout A549 cell line (AB266996)
  • Sanger seq

Lab

Sanger Sequencing - Human TRIM22 knockout A549 cell line (AB266996)

Sequencing chromatogram displaying sequence edit in exon 3

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 8 bp deletion in exon 3

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266996-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266996 Human TRIM22 knockout A549 cell line", "number":"AB266996-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB266996-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266996-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266996 Human TRIM22 knockout A549 cell line", "number":"AB266996-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB266996-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266996-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266996 Human TRIM22 knockout A549 cell line", "number":"AB266996-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266996-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266996 Human TRIM22 knockout A549 cell line", "number":"AB266996-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TRIM22
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRIM22 also known as Staf50 is a protein encoded by the TRIM22 gene. It weighs approximately 56 kDa. TRIM22 is expressed in different tissues throughout the body including the spleen thymus and liver. This protein belongs to the tripartite motif (TRIM) family which is characterized by a distinct structure comprising a RING finger B-box domains and a coiled-coil region. The presence of a RING finger domain suggests that TRIM22 might have E3 ubiquitin ligase activity.
Biological function summary

TRIM22 plays a significant role in innate immunity influencing the antiviral response. As an E3 ubiquitin ligase it facilitates the ubiquitination and degradation of host proteins that are involved in viral replication processes. TRIM22 does not generally function in a protein complex but it interacts with other proteins in a cellular context. This interaction enhances the cellular response against viral infections by disrupting viral components and inhibiting viral replication.

Pathways

TRIM22 is involved in the IFN (interferon) signaling pathway which is essential for the immune response against pathogens. In this pathway TRIM22 interacts with proteins like IFNAR1 and STAT1 acting as a mediator of antiviral activities. It also participates in the ubiquitin-proteasome system aiding in the regulation of protein turnover within the cell. These pathways demonstrate the broad scope of TRIM22 in maintaining cellular homeostasis and responding to external immune challenges.

TRIM22 has been linked to conditions such as systemic lupus erythematosus (SLE) and certain cancers. In SLE TRIM22 expression is often dysregulated contributing to an altered immune response. The protein also connects with STAT proteins which can be influential in autoimmune disease pathways. Moreover aberrant expression of TRIM22 has been observed in some cancer types suggesting a role in tumor biology and potentially offering a target for therapeutic intervention.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com